MSInsight Joins PREDI-LYNCH Project for Non-Invasive Cancer Detection
MSInsight, a pioneering precision oncology start-up from France, has recently announced its participation in the innovative PREDI-LYNCH project. This significant initiative, associated with the Horizon Europe consortium, aims to create validated liquid biopsy tests to enhance early cancer detection, particularly in individuals affected by Lynch syndrome (LS), a well-known hereditary cancer disorder.
Understanding Lynch Syndrome and Its Implications
Lynch syndrome is linked to inherited mutations in the DNA mismatch repair (MMR) genes, resulting in an elevated lifetime risk of various cancers, including colorectal, endometrial, and ovarian cancers. Those with Lynch syndrome are facing a substantial risk, with estimates indicating that 50-80% may develop colorectal cancer during their lifetimes. Specific genes contribute differently to these risks, making it crucial to understand the connection between genetics and cancer risk.
Project Goals: Advancements in Early Detection
The PREDI-LYNCH initiative, launched in May 2025, aims to address the significant diagnostic gap present in the current monitoring of Lynch syndrome carriers. Epidemiological studies suggest that while approximately 1 in 440 individuals of European descent carry these genetic mutations, only about 5% are actively monitored. This gap highlights a critical public health issue, as many individuals remain undiagnosed and at risk.
The project has a total financial backing of €13.6 million, coordinated by Oslo University Hospital, and brings together 28 esteemed institutions from 16 European nations. The focus will be on:
- Developing non-invasive liquid biopsy tests tailored for colorectal, endometrial, and urothelial cancers.
- Conducting multi-center trials to validate biomarkers across diverse healthcare systems.
- Integrating AI technologies to enhance the discovery and monitoring of these crucial biomarkers.
- Evaluating socio-economic considerations to ensure that new diagnostic methods are accessible and effective for patients.
MSInsight’s Contribution to Innovative Diagnostics
Within the context of PREDI-LYNCH, MSInsight is leveraging its deep expertise in microsatellite instability (MSI) diagnostics, which plays a pivotal role in the understanding of Lynch syndrome-related cancers. The company’s MSIcare platform utilizes advanced next-generation sequencing and artificial intelligence techniques to improve the precision of MSI detection.
This integration aims not only to enhance liquid biopsy applications but also to establish a non-invasive technique for cancer prediction and monitoring among individuals carrying Lynch syndrome-associated mutations.
Raising Awareness During Hereditary Cancer Awareness Week
The announcement of MSInsight's involvement coincides with Hereditary Cancer Awareness Week, which aims to spotlight the importance of recognizing genetic risks. Awareness is often the first step toward implementing life-saving interventions, such as increased surveillance and early detection practices among at-risk populations.
In addition to focusing on Lynch syndrome, MSInsight is expanding its efforts to include the diagnosis of children affected by Constitutional Mismatch Repair Deficiency (CMMRD), a rare syndrome with serious implications for young patients.
About MSInsight: Innovating Cancer Care
Founded in Paris in 2022, MSInsight is dedicated to revolutionizing cancer diagnostics through cutting-edge technologies. Building on two decades of academic research from Sorbonne University, the company significantly emphasizes precision diagnostics and patient-centered healthcare solutions.
The company's flagship platform has already gained clinical validation in tumor tissue and is now moving towards non-invasive blood-based applications, aiming to reshape the landscape of cancer care profoundly.
Frequently Asked Questions
What is the PREDI-LYNCH project?
PREDI-LYNCH is a Horizon Europe initiative aimed at developing non-invasive liquid biopsy tests for early cancer detection in Lynch syndrome carriers.
What role does MSInsight play in the project?
MSInsight brings its expertise in microsatellite instability diagnostics, contributing technology to enhance non-invasive cancer prediction methods.
Why is Lynch syndrome significant in cancer research?
Lynch syndrome is associated with a high risk of various cancers and understanding it can greatly improve early detection and treatment outcomes.
How does population awareness improve health outcomes?
Increasing awareness of hereditary cancers helps individuals recognize their risks and seek timely medical interventions.
What future prospects does MSInsight envision?
MSInsight aims to expand its diagnostic solutions and improve patient outcomes through innovative, non-invasive technologies in oncology.
